Studies on fungal pyripyropenes, potent inhibitors of cholesterol metabolism
Studies on fungal pyripyropenes, potent inhibitors of cholesterol metabolism
批准号:
07457525
负责人:
OMURA Satoshi
金额:
$4.99万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1997
中文摘要
土壤分离的烟曲霉FO-1289产生一系列新的酰基辅酶A抑制剂:胆固醇酰基转移酶(ACAT)。通过溶剂萃取、硅胶、LH20和ODS柱层析及制备型高效液相色谱分析,从该菌株发酵液中分离得到19个化合物,命名为吡喃甲烯A至S,为白色粉末或无色结晶,其结构经核磁共振及其它波谱研究证实。它们都有一个共同的碳骨架,由吡啶、α-吡喃酮和倍半萜组成。通过X射线结晶学和Mosher方法的Kakisawa-Kashman修正,阐明了吡喃A的相对和绝对立体化学。用不同的[^<;13>;C]和[^<;14>;C]前体进行投料实验,研究了吡啶类化合物A的生物合成来源。核磁共振和降解分析表明,吡啶-α-吡喃酮部分是由底物烟酸与两个a-…缩合而成。更多的乙酸酯,倍半萜部分是由三个甲氧戊酸酯产生的,然后三个乙酰基从乙酸酯引入到核心骨架中。用大鼠肝微粒体酶活性测定ACAT抑制活性。其中,吡啶类化合物C、A、L和B表现出很强的抑制活性,其IC50分别为0.15、0.16、0.27和0.32微米,表明这些吡喃类化合物是迄今报道的最有效的天然ACAT抑制剂。基于天然吡啶类化合物的构效关系,合成了约300个衍生物,以寻找比吡喃A更有效的抑制剂(PR-45、PR-86和PR-109)。此外,还实现了吡喃A和E的全合成。在仓鼠模型中,吡喃A及其部分衍生物被证明具有减少肠道胆固醇吸收的效果。较少
英文摘要
A soil isolated Aspergillus fumigatus FO-1289 was found to produce a series of novel inhibitors of acyl-CoA : cholesterol acyltransferase (ACAT). Nineteen compounds named pyraipyraopenes A to S were isolated as white powders or colorless crystals from the fermentation broth of the producer by solvent extraction, silica gel, LH20 and ODS column chromatographies, and preparative HPLC.The structures were e ; icodated by NMR and other spectroscopic studies. They have a common carbon skeleton which consists of pyridine, alpha-pyrone and sesquiterpene moieties. The relative and absolute stereochemistry of pyripyropenes A was elucidated via X-ray crystallography and the Kakisawa-Kashman modification of Mosher's NMR method. The biosynthetic origin of pyripyropenes A was studied by feeding experiments using various [^<13>C] and [^<14>C]precursors. ^<13>C NMR and degradation analyzes proposed that the pyridino-alpha-pyrone moiety is produced via condensation of a primer nicotinic acid with two a … More cetates, the sesquiterpene moiety is produced from three mevalonates, and then three acetly residues are introduced from acetates into the core skelton. ACAT inhibitory activity was tested in an enzyme assay using rat liver microsomes. Among them pyripyropenes C,A,L and B showed very potent inhibirtory activity with IC_<50> values of 0.15,0.16,0.27 and 0.32 muM,respectively, indicating that these pyripyropenes represent the most potent naturally occurring ACAT inhibitors reported to date. Acyloxy groups are essential at both R1 and R2 positions in the molecules for exhibiting potent ACAT inhibition.Based on the structure-activity relationships of nataural pyripyraopenes, about 300 derivatives were prepared, achieving to find more potent inhibitors (PR-45, PR-86 and PR-109) that pyripyropene A.Futhermore, total synthesis of pyripyropenes A and E were also achieved.In vivo efficacy of pyripyropene A and selected derivatives was demonstrated in a hamster model reducing the cholesterol absorption from intestines. Less
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Tomoda H.: "Biosynthesis of pyripyropene A." J.Org.Chem. 61. 882-886 (1996)
Tomoda H.:“pyripyropene A 的生物合成”。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Obata R: "Structure-activity relationships of pyripyropenes,fungal acyl-CoA:cholesterol acyltransferase inhibitors." J.Antibiot. 48. 749-750 (1995)
Obata R:“pyripyropenes、真菌酰基辅酶A:胆固醇酰基转移酶抑制剂的结构-活性关系。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
供田ら: "Biosynfhesis of pyripyropene A" J.Org.Chem.61. 882-886 (1996)
Toda 等人:“pyripyropene A 的生物合成”J.Org.Chem.61 (1996)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Obata R.: "Chemical modification and structure-activity relationships of pyripyropenes;potent,bioavailable inhibitor of acyl-CoA:cholesterol O-asyltransferase(ACAT)." Bioorg.Med.Chem.Lett.5. 2683-2688 (1995)
Obata R.:“pyripyropenes 的化学修饰和结构活性关系;酰基辅酶 A 的有效生物利用抑制剂:胆固醇 O-酰基转移酶 (ACAT)。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
長光ら: "Total synthesis of (+) pyripyropene A" J.Org.Chem.60. 8126-8127 (1995)
Nagamitsu 等人:“(+)pyripyropene A 的全合成”J.Org.Chem.60 (1995)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 14 条
Research of the antimalarial drugs from the natural products
-
批准号:11307052
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$25.77万
-
财政年份:1999
-
负责人:OMURA Satoshi
-
依托单位:
Inhibition of foam cell formation : Application to the discovery of novel antiatherosclerotic agents
-
批准号:02557094
-
项目类别:Grant-in-Aid for Developmental Scientific Research (B)
-
资助金额:$9.54万
-
财政年份:1990
-
负责人:OMURA Satoshi
-
依托单位:
Construction of Streptomyces-Eschetichia coli bifunctional cosmid and cloning of antibiotic biosynthetic genes.
-
批准号:61571079
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:1986
-
负责人:OMURA Satoshi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACAT1乳酸化修饰通过自噬调控产蛋后期蛋鸡排卵的分子机制研究
-
批准号:32502889
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:聂瑞雪
-
依托单位:
ACAT2调控KRT8乳酸化修饰介导肺泡上皮细胞衰老在臭氧所致肺纤维化中的作用机制研究
-
批准号:82504363
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:王佩雯
-
依托单位:
ACAT-1介导胆固醇酯蓄积在宫颈癌细胞内的促癌机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:毛世杰
-
依托单位:
PICH通过转录激活ACAT1介导脂代谢重编程促进胃癌免疫逃逸的机制研究
-
批准号:82460500
-
项目类别:地区科学基金项目
-
资助金额:32.00万元
-
批准年份:2024
-
负责人:冶慧丽
-
依托单位:
益肾清利活血方调控ACAT1乙酰化修饰TFEB修复自噬流改善肾纤维化的机制研究
-
批准号:82374373
-
项目类别:面上项目
-
资助金额:45万元
-
批准年份:2023
-
负责人:孙伟
-
依托单位:
ACAT1通过内质网-线粒体互作调控线粒体稳态在棕色脂肪细胞中的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:周章森
-
依托单位:
ACAT1作为CHK1抑制剂抗急性髓系白血病耐药生物标志物和联用靶点的探索性研究
-
批准号:82304539
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:姜凯龙
-
依托单位:
基于ACAT2/FASN/AcAc-CoA调控轴探讨促进脂肪酸合成代谢对抗血管内皮衰老的分子机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:罗文威
-
依托单位:
ACAT1通过溶酶体途径抑制脑出血后小胶质细胞持续吞噬能力的作用和机制研究
-
批准号:82371299
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:陈高
-
依托单位:
乳腺癌CDK4/6抑制剂耐药新机制:ACAT2代谢物Meta2靶向调控YAP构象及活性促进其核转位的机制研究
-
批准号:82303834
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:孙茜
-
依托单位: